Nutrition 21 (NXXI) soared 62% after the company received a purchase order from Rite Aid (RAD - Get Report) for the company's Chromax chromium picolinate product. The product will be distributed to more than 3,400 Rite Aid stores and mark the first time that Nutrition 21's Chromax product will be available in retail stores. "Our direct distribution strategy is on schedule," the company said in a statement. "The Rite Aid commitment is a significant initial step in our transition from primarily a wholesale ingredients supplier to also a supplier of branded finished goods." Shares were trading up 43 cents to $1.12.Other health care volume movers included Pfizer (PFE), down 6 cents to $24.52; Guidant (GDT), up 50 cents to $70.90; Elan (ELN), down 17 cents to $16.02; Bristol-Myers Squibb (BMY), down 16 cents to $22.30; Nektar Therapeutic (NKTR), up $1.79 to $19.90; UnitedHealth Group (UNH), down $2.12 to $60.41; Boston Scientific (BSX), up 3 cents to $25.08; Amgen (AMGN), up 55 cents to $77.75; Johnson & Johnson (JNJ), down 64 cents to $61.57; Merck (MRK), up 11 cents to $33.59; and Schering-Plough (SGP), down 22 cents to $20.11.
Health Stocks in Motion
Check Out Our Best Services for Investors
Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts